Oligomeric self-association contributes to E2A-PBX1-mediated oncogenesis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 03 2019
Historique:
received: 23 09 2018
accepted: 04 03 2019
entrez: 22 3 2019
pubmed: 22 3 2019
medline: 6 10 2020
Statut: epublish

Résumé

The PBX1 homeodomain transcription factor is converted by t(1;19) chromosomal translocations in acute leukemia into the chimeric E2A-PBX1 oncoprotein. Fusion with E2A confers potent transcriptional activation and constitutive nuclear localization, bypassing the need for dimerization with protein partners that normally stabilize and regulate import of PBX1 into the nucleus, but the mechanisms underlying its oncogenic activation are incompletely defined. We demonstrate here that E2A-PBX1 self-associates through the PBX1 PBC-B domain of the chimeric protein to form higher-order oligomers in t(1;19) human leukemia cells, and that this property is required for oncogenic activity. Structural and functional studies indicate that self-association facilitates the binding of E2A-PBX1 to DNA. Mutants unable to self-associate are transformation defective, however their oncogenic activity is rescued by the synthetic oligomerization domain of FKBP, which confers conditional transformation properties on E2A-PBX1. In contrast to self-association, PBX1 protein domains that mediate interactions with HOX DNA-binding partners are dispensable. These studies suggest that oligomeric self-association may compensate for the inability of monomeric E2A-PBX1 to stably bind DNA and circumvents protein interactions that otherwise modulate PBX1 stability, nuclear localization, DNA binding, and transcriptional activity. The unique dependence on self-association for E2A-PBX1 oncogenic activity suggests potential approaches for mechanism-based targeted therapies.

Identifiants

pubmed: 30894657
doi: 10.1038/s41598-019-41393-w
pii: 10.1038/s41598-019-41393-w
pmc: PMC6426973
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
DNA, Neoplasm 0
Oncogene Proteins, Fusion 0
Pre-B-Cell Leukemia Transcription Factor 1 0
TCF3 protein, human 0
PBX1 protein, human 0
Tacrolimus Binding Proteins EC 5.2.1.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4915

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR001083
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001085
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214888
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA124435
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003142
Pays : United States

Références

Cancer Cell. 2015 Aug 10;28(2):198-209
pubmed: 26190263
J Biol Chem. 2006 Sep 8;281(36):25926-39
pubmed: 16757478
Blood. 2004 May 15;103(10):3876-82
pubmed: 14751928
Cancer Cell. 2003 Aug;4(2):99-110
pubmed: 12957285
Mol Cell Biol. 1999 Jul;19(7):5134-42
pubmed: 10373562
Nature. 2013 Aug 1;500(7460):93-7
pubmed: 23812588
Cancer Genet Cytogenet. 1986 Jan 15;19(3-4):261-9
pubmed: 3455845
J Clin Invest. 2015 Sep;125(9):3667-80
pubmed: 26301816
Mol Cell Biol. 2006 Aug;26(15):5650-62
pubmed: 16847320
Mol Cell Biol. 1991 Dec;11(12):6149-57
pubmed: 1682799
Genes Dev. 1995 Mar 15;9(6):663-74
pubmed: 7729685
Cell. 1990 Feb 23;60(4):547-55
pubmed: 1967983
Oncogene. 1994 Jun;9(6):1641-7
pubmed: 8183558
Biochim Biophys Acta. 1997 Dec 9;1333(3):F217-48
pubmed: 9426205
Cancer Cell. 2003 Sep;4(3):197-207
pubmed: 14522254
Leuk Lymphoma. 2003 Jul;44(7):1187-99
pubmed: 12916872
Cancer Cell. 2006 Apr;9(4):249-60
pubmed: 16616331
Front Biosci. 2003 May 01;8:s206-22
pubmed: 12700034
Nat Commun. 2017 Oct 23;8(1):1099
pubmed: 29062045
Development. 2000 Jan;127(1):155-66
pubmed: 10654609
Science. 1993 Nov 12;262(5136):1019-24
pubmed: 7694365
Mol Cell Biol. 1993 Dec;13(12):7321-33
pubmed: 8246953
Dev Dyn. 2014 Jan;243(1):145-58
pubmed: 23996689
Mol Cell Biol. 1999 Sep;19(9):6355-66
pubmed: 10454582
Mol Cell Biol. 2005 Oct;25(19):8541-52
pubmed: 16166636
Cancer Cell. 2006 Feb;9(2):81-94
pubmed: 16473276
Mol Cell. 2003 Aug;12(2):393-400
pubmed: 14536079
Cell. 1990 Feb 23;60(4):535-45
pubmed: 1967982
Dev Biol. 2004 Dec 15;276(2):301-12
pubmed: 15581866
Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14553-8
pubmed: 9405651
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9238-43
pubmed: 16757557
Oncogene. 2008 Oct 23;27(49):6356-64
pubmed: 18679416
Mol Cell Biol. 1995 Jul;15(7):3786-95
pubmed: 7791786
Mol Cell Biol. 1994 Dec;14(12):8304-14
pubmed: 7969166
Immunol Rev. 2005 Jun;205:30-47
pubmed: 15882343
Mol Cell Biol. 1997 Oct;17(10):5679-87
pubmed: 9315626
Oncogene. 2001 Sep 10;20(40):5708-17
pubmed: 11607820
Mol Cell Biol. 1996 Apr;16(4):1632-40
pubmed: 8657138
Mol Cell Biol. 1997 Jan;17(1):81-8
pubmed: 8972188
EMBO J. 1997 Jul 16;16(14):4226-37
pubmed: 9250666
Genes Dev. 1999 Apr 15;13(8):946-53
pubmed: 10215622
Oncogene. 1999 Dec 23;18(56):8033-43
pubmed: 10637514
Sci STKE. 2005 Jan 11;2005(266):pl1
pubmed: 15644491
Cell. 2017 Apr 20;169(3):407-421.e16
pubmed: 28431242
Dev Cell. 2008 Dec;15(6):854-65
pubmed: 19081074
Genes Dev. 1998 Feb 1;12(3):435-46
pubmed: 9450936
Cell. 1994 Aug 26;78(4):617-24
pubmed: 7915200
EMBO J. 1994 Aug 1;13(15):3561-9
pubmed: 7914871
Cell. 1997 Oct 17;91(2):171-83
pubmed: 9346235
Oncogene. 1996 Jan 4;12(1):19-30
pubmed: 8552391
Cell. 2013 Feb 14;152(4):909-22
pubmed: 23394947
Blood. 2004 Aug 15;104(4):919-22
pubmed: 15130940
Science. 1997 Nov 7;278(5340):1059-64
pubmed: 9353180

Auteurs

Chiou-Hong Lin (CH)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Zhong Wang (Z)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Sun Yat-Sen University, School of Pharmaceutical Sciences, Guangzhou, 510006, China.

Jesús Duque-Afonso (J)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany.

Stephen Hon-Kit Wong (SH)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Janos Demeter (J)

Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Alexander V Loktev (AV)

Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Tim C P Somervaille (TCP)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, M20 4GJ, UK.

Peter K Jackson (PK)

Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Michael L Cleary (ML)

Department of Pathology, Stanford University School of Medicine, Stanford, CA, 94305, USA. mcleary@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH